Clinical Research Directory

Patients can be enrolled, when they fulfil the following inclusion criteria: * Written informed consent to participate. * At least 18 years of age. * Patients suffering from documented primary hypercholesterolemia or mixed dyslipidaemia treated or intended to be treated with bempedoic acid/ FDC with ezetimibe at the discretion of the physician are appropriate for participation in the observation. * For patients who are treated with bempedoic acid/FDC with ezetimibe prior to signed informed consent, initiation of bempedoic acid/FDC with ezetimibe must be within a maximum of three months prior to inclusion. * No contraindications exist according to the SmPC of bempedoic acid/FDC with ezetimibe. * No concurrent participation in an interventional study (simultaneous participation in other non-interventional study is possible) * Life expectancy \> 1 year. No explicit exclusion criteria exist to avoid selection bias and to allow for documentation of routine clinical practice.